A Study of Mitoguazone Dihydrochloride in Patients With AIDS-Related Non-Hodgkin's Lymphoma

Exclusion Criteria

• •Co-existing Condition:
• •Patients with the following symptoms and conditions are excluded:
• •Concomitant malignancy OTHER THAN curatively treated carcinoma in situ of the cervix; basal or squamous cell carcinoma of the skin; or non-active, non-visceral Kaposi's sarcoma not requiring active chemotherapy.
• •Active uncontrolled bacterial infection, viral infection (other than herpes simplex), or fungal infection (other than oropharyngeal candidiasis) that requires treatment within 2 weeks of study entry.
• •Significant cardiovascular disease.
• •Concurrent Medication:
• •Excluded:
• •Hormonal therapy (except medications given for muscle wasting, such as testosterone or Megace).
• •Other chemotherapy.
• •Investigational anti-cancer drugs.
• •Concurrent Treatment:
• •Excluded:
• •Concomitant radiation to sites other than CNS.
• •Patients with the following prior conditions are excluded:
• •Prior malignancy OTHER THAN curatively treated carcinoma in situ of the cervix; basal or squamous cell carcinoma of the skin; or non-active, non-visceral Kaposi's sarcoma not requiring active chemotherapy.
• •Recommended:
• •Prophylaxis for PCP and oral candidiasis.
• •Required in patients with leptomeningeal disease:
• •Intrathecal methotrexate or cytarabine (Ara-C).
• •Leucovorin.
• •Required in patients with leptomeningeal disease:
• •Cranial radiation to a helmet field.